US Poliovirus Containment Survey
Welcome and thank you for participating in the U.S. National Inventory for Poliovirus Containment!
This survey is supported by the U.S. Poliovirus National Authority for Containment (NAC), at the Centers for Disease Control and Prevention, Center for Preparedness and Response (formerly the Office of Public Health Preparedness and Response). This survey is designed to collect relevant laboratory inventory data and ensure compliance with recommendations established in the WHO Global Action Plan (GAPIII), as adapted for the WHO Region of the Americas. In accordance with these recommendations, each country is required to complete a national inventory of poliovirus-containing materials. Unlike previous surveys, the 2018 survey focuses on institutions that may have poliovirus potentially infectious materials (PIM). PIM includes human respiratory secretion and fecal specimens, or environmental samples collected for non-polio related work in a time and geographic area where wild poliovirus (WPV) or vaccine-derived poliovirus (cVDPV) was circulating or where oral polio vaccine (OPV) was used. Historical and international specimens are more likely to fall into these categories. Also, in order to isolate other viruses of interest, PIM cultured in some common cell lines (see Survey Guidance Document: Appendix C: Common Cell Lines and Animals Susceptible to Poliovirus*) may have amplified poliovirus unintentionally. Respiratory or enteric viral isolates obtained from PIM specimens using any of these cell lines are considered PIM.
Laboratories, storage sites, or other facilities that test, extract, handle, or store biological samples from humans, experimentally infected animals, sewage, or environmental waters should complete the survey. The questions are intended to identify facilities possessing any materials that could potentially contain poliovirus. The questions seek to distinguish between PIM containing wild poliovirus (WPV), circulating vaccine derived poliovirus (cVDPV), and oral poliovirus vaccine (OPV). With the release of the WHO PIM guidance in April 2018, specimens that may contain only OPV are no longer subject to containment under WHO GAP III. However, they are still considered to be part of the US inventory and should be reported. Information provided on this record may be provided to WHO poliovirus containment oversight bodies for reporting purposes in compliance with GAPIII.
For the purpose of this survey, PIM should be identified on the basis of where and when the specimens were collected, not on the basis of any test results (see Survey Guidance Document: Appendix E:Summary of Country Information on Last Known Polio Cases for additional information*).
*The NIPC Survey Guidance document can be downloaded by clicking the icon on the next screen.
CDC has determined that the information collection activities conducted under this project are exempt from the requirements of the Paperwork Reduction Act (PRA) as they fall under the activities authorized under the National Childhood Vaccine Injury Act (NCVIA) at section 2102(a)(6)-(a)(7) of the Public Health Service Act (42 USC 300aa-2(a)(6)-(a)(7).
Page 1 of 25